CRANBURY, N.J., May 8, 2023
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American:
PTN), a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor system, today hosted a key opinion leader
(KOL) webinar presenting data from the Lead-In population of the
ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye
Disease.
The webinar was moderated by Carl
Spana, Ph.D., President & CEO of Palatin, and featured
Bruce C. Stouch, Ph.D. (Philadelphia College of Osteopathic Medicine) and
George Ousler, M.S. (Senior Vice
President of Anterior Segment, Ora) and Michael B. Raizman, M.D., practicing
ophthalmologist and CMO of Palatin.
The data highlighted the excellent ocular tolerability of PL9643
eye drops and the broad efficacy on the signs and symptoms of dry
eye disease.
The KOL presentation was followed by a question-and-answer
session with Dr. Stouch, Mr. Ousler, Dr. Raizman, Dr. Spana and
Stephen T. Wills. To listen to a
replay of the webinar please go to Palatin's website at
www.palatin.com or click here.
About Dry Eye Disease (DED)
Dry eye disease is a common inflammatory disease that, left
untreated, can become extremely painful and lead to permanent
damage to the cornea and vision. DED affects the cornea and
conjunctiva of the eye resulting in irritation, redness, pain, and
blurred vision. It is estimated to affect over 20 million people in
the United States. The disease is
characterized by insufficient moisture and lubrication in the
anterior surface of the eye, leading to dryness, inflammation,
pain, discomfort, irritation, diminished quality of life, and in
severe cases, permanent vision impairment. Existing therapy for DED
is generally regarded as inadequate by many physicians and
patients, and often requires weeks or months to demonstrate
activity.
About Melanocortin Receptor Agonists and Inflammation
The melanocortin receptor ("MCr") system has effects on
inflammation, immune system responses, metabolism, food intake, and
sexual function. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects. Many tissues
and immune cells located throughout the body, including the gut,
kidney and eye, express melanocortin receptors, empowering our
opportunity to directly activate natural pathways to resolve
disease inflammation. Drugs based on melanocortin agonists have
been approved by the FDA for treating several conditions, including
female sexual dysfunction, inflammatory/autoimmune diseases, and
rare forms of genetic obesity.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor systems, with targeted, receptor-specific
product candidates for the treatment of diseases with significant
unmet medical need and
commercial potential. Palatin's strategy
is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com and follow
Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin, such as
statements about PL9643 clinical results, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and as
that
term is defined in the Private Securities Litigation Reform Act of 1995.
Palatin intends that such forward-looking statements be
subject to the safe harbors created thereby. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that could cause Palatin's actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating events that
occur after the date of this press release.
Palatin Technologies® is a registered trademark of
Palatin Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-invites-investors-to-listen-to-replay-of-the-pl9643-dry-eye-disease-key-opinion-leader-webinar-301818653.html
SOURCE Palatin Technologies, Inc.